CA2926845C - Salt and crystal forms of plk-4 inhibitor - Google Patents
Salt and crystal forms of plk-4 inhibitor Download PDFInfo
- Publication number
- CA2926845C CA2926845C CA2926845A CA2926845A CA2926845C CA 2926845 C CA2926845 C CA 2926845C CA 2926845 A CA2926845 A CA 2926845A CA 2926845 A CA2926845 A CA 2926845A CA 2926845 C CA2926845 C CA 2926845C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- salt
- fumarate
- fumarate salt
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361892564P | 2013-10-18 | 2013-10-18 | |
| US61/892,564 | 2013-10-18 | ||
| PCT/CA2014/051001 WO2015054793A1 (en) | 2013-10-18 | 2014-10-17 | Salt and crystal forms of plk-4 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2926845A1 CA2926845A1 (en) | 2015-04-23 |
| CA2926845C true CA2926845C (en) | 2023-06-13 |
Family
ID=52827507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2926845A Active CA2926845C (en) | 2013-10-18 | 2014-10-17 | Salt and crystal forms of plk-4 inhibitor |
Country Status (27)
| Country | Link |
|---|---|
| US (5) | US9884855B2 (https=) |
| EP (1) | EP3057965B1 (https=) |
| JP (1) | JP6492072B2 (https=) |
| KR (3) | KR102395737B1 (https=) |
| CN (2) | CN105764899B (https=) |
| AU (1) | AU2014336929B9 (https=) |
| CA (1) | CA2926845C (https=) |
| CY (1) | CY1121484T1 (https=) |
| DK (1) | DK3057965T3 (https=) |
| EA (1) | EA031569B1 (https=) |
| ES (1) | ES2718603T3 (https=) |
| HR (1) | HRP20190564T1 (https=) |
| HU (1) | HUE043194T2 (https=) |
| IL (1) | IL245038B (https=) |
| LT (1) | LT3057965T (https=) |
| ME (1) | ME03377B (https=) |
| MX (1) | MX359069B (https=) |
| NZ (1) | NZ718744A (https=) |
| PL (1) | PL3057965T3 (https=) |
| PT (1) | PT3057965T (https=) |
| RS (1) | RS58413B1 (https=) |
| SG (1) | SG11201602783SA (https=) |
| SI (1) | SI3057965T1 (https=) |
| SM (1) | SMT201900124T1 (https=) |
| TR (1) | TR201902875T4 (https=) |
| TW (1) | TWI659952B (https=) |
| WO (1) | WO2015054793A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5629752B2 (ja) | 2009-04-06 | 2014-11-26 | ユニバーシティ・ヘルス・ネットワークＵｎｉｖｅｒｓｉｔｙ Ｈｅａｌｔｈ Ｎｅｔｗｏｒｋ | キナーゼインヒビターおよびこれを用いた癌の治療方法 |
| JP5442906B2 (ja) | 2010-04-06 | 2014-03-19 | ユニバーシティ・ヘルス・ネットワーク | キナーゼインヒビターおよびこれを用いた癌の治療方法 |
| RS58413B1 (sr) | 2013-10-18 | 2019-04-30 | Univ Health Network | So i kristalni oblici inhibitora plk-4 |
| AU2018328773B2 (en) * | 2017-09-08 | 2023-11-16 | University Health Network | Combination therapies for inhibition of Polo-like Kinase 4 |
| SG11202111003UA (en) * | 2019-04-24 | 2021-11-29 | Univ Health Network | Crystal form s4 of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate |
| JP2023505301A (ja) * | 2019-12-06 | 2023-02-08 | ユニバーシティー ヘルス ネットワーク | 急性骨髄性白血病または骨髄異形成症候群に対する治療 |
| MX2023013225A (es) | 2021-05-11 | 2024-01-15 | Oric Pharmaceuticals Inc | Inhibidores de la cinasa 4 similar a polo. |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2483323A (en) * | 1945-08-01 | 1949-09-27 | Kay Fries Chemicals Inc | Method of preparing phenyl ethyl alcohol |
| US7205328B2 (en) | 2002-10-21 | 2007-04-17 | Irm Llc | Oxindoles with anti-HIV activity |
| DE102005005395A1 (de) | 2005-02-03 | 2006-08-10 | Schering Aktiengesellschaft | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| GB0606234D0 (en) * | 2006-03-29 | 2006-05-10 | Pliva Istrazivanje I Razvoj D | Pharmaceutically acceptable salts and polymorphic forms |
| WO2008118097A1 (en) * | 2007-03-23 | 2008-10-02 | Agency For Science, Technology And Research | Palladium catalysts |
| WO2009042711A1 (en) * | 2007-09-25 | 2009-04-02 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| EP2235004A4 (en) | 2007-12-21 | 2011-05-04 | Univ Health Network | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT |
| JP5629752B2 (ja) * | 2009-04-06 | 2014-11-26 | ユニバーシティ・ヘルス・ネットワークＵｎｉｖｅｒｓｉｔｙ Ｈｅａｌｔｈ Ｎｅｔｗｏｒｋ | キナーゼインヒビターおよびこれを用いた癌の治療方法 |
| EP2424868B1 (en) * | 2009-04-29 | 2018-01-10 | Nerviano Medical Sciences S.r.l. | Cdk inhibitor salts |
| JP5442906B2 (ja) * | 2010-04-06 | 2014-03-19 | ユニバーシティ・ヘルス・ネットワーク | キナーゼインヒビターおよびこれを用いた癌の治療方法 |
| US8933070B2 (en) | 2010-07-02 | 2015-01-13 | University Health Network | Methods of targeting PTEN mutant diseases and compositions therefor |
| WO2012048411A1 (en) | 2010-10-13 | 2012-04-19 | University Health Network | Plk-4 inhibitors and method of treating cancer with same |
| CN103476770B (zh) * | 2010-11-25 | 2017-02-15 | 拉蒂欧制药有限责任公司 | 阿法替尼盐和多晶型物 |
| EP2766352B1 (en) | 2011-10-12 | 2018-06-06 | University Health Network (UHN) | Indazole compounds as kinase inhibitors and method of treating cancer with same |
| RS58413B1 (sr) | 2013-10-18 | 2019-04-30 | Univ Health Network | So i kristalni oblici inhibitora plk-4 |
| SG11201602882VA (en) | 2013-10-18 | 2016-05-30 | Univ Health Network | Treatment for pancreatic cancer |
-
2014
- 2014-10-17 RS RS20190269A patent/RS58413B1/sr unknown
- 2014-10-17 PT PT14854037T patent/PT3057965T/pt unknown
- 2014-10-17 MX MX2016004963A patent/MX359069B/es active IP Right Grant
- 2014-10-17 ME MEP-2019-97A patent/ME03377B/me unknown
- 2014-10-17 SI SI201431110T patent/SI3057965T1/sl unknown
- 2014-10-17 KR KR1020217036751A patent/KR102395737B1/ko active Active
- 2014-10-17 CN CN201480064037.9A patent/CN105764899B/zh active Active
- 2014-10-17 NZ NZ718744A patent/NZ718744A/en unknown
- 2014-10-17 HU HUE14854037A patent/HUE043194T2/hu unknown
- 2014-10-17 WO PCT/CA2014/051001 patent/WO2015054793A1/en not_active Ceased
- 2014-10-17 AU AU2014336929A patent/AU2014336929B9/en active Active
- 2014-10-17 TW TW103135953A patent/TWI659952B/zh active
- 2014-10-17 HR HRP20190564TT patent/HRP20190564T1/hr unknown
- 2014-10-17 DK DK14854037.0T patent/DK3057965T3/en active
- 2014-10-17 PL PL14854037T patent/PL3057965T3/pl unknown
- 2014-10-17 SM SM20190124T patent/SMT201900124T1/it unknown
- 2014-10-17 ES ES14854037T patent/ES2718603T3/es active Active
- 2014-10-17 CA CA2926845A patent/CA2926845C/en active Active
- 2014-10-17 EP EP14854037.0A patent/EP3057965B1/en active Active
- 2014-10-17 CN CN202110510808.4A patent/CN113248486A/zh active Pending
- 2014-10-17 KR KR1020227015022A patent/KR20220063299A/ko not_active Ceased
- 2014-10-17 US US15/029,373 patent/US9884855B2/en active Active
- 2014-10-17 LT LTEP14854037.0T patent/LT3057965T/lt unknown
- 2014-10-17 SG SG11201602783SA patent/SG11201602783SA/en unknown
- 2014-10-17 TR TR2019/02875T patent/TR201902875T4/tr unknown
- 2014-10-17 JP JP2016524077A patent/JP6492072B2/ja active Active
- 2014-10-17 EA EA201690755A patent/EA031569B1/ru not_active IP Right Cessation
- 2014-10-17 KR KR1020167012155A patent/KR20160070106A/ko not_active Ceased
-
2016
- 2016-04-11 IL IL24503816A patent/IL245038B/en active IP Right Grant
-
2018
- 2018-02-01 US US15/886,104 patent/US10392374B2/en active Active
-
2019
- 2019-03-22 CY CY20191100336T patent/CY1121484T1/el unknown
- 2019-04-19 US US16/389,119 patent/US10472353B2/en active Active
- 2019-11-06 US US16/675,609 patent/US10919886B2/en active Active
-
2021
- 2021-02-10 US US17/172,511 patent/US11667627B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11667627B2 (en) | Salt and crystal forms of PLK-4 inhibitor | |
| AU2014336929A1 (en) | Salt and crystal forms of PLK-4 inhibitor | |
| US11878980B2 (en) | Solid forms of TTK inhibitor | |
| SG11202111003UA (en) | Crystal form s4 of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate | |
| HK1227404B (en) | Salt and crystal forms of plk-4 inhibitor | |
| HK1227404A1 (en) | Salt and crystal forms of plk-4 inhibitor | |
| EA044843B1 (ru) | Кристаллическая форма ингибитора plk4 | |
| HK40007702B (en) | Solid forms of ttk inhibitor | |
| HK40007702A (en) | Solid forms of ttk inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20191016 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241011 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241011 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251203 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260413 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260413 |